Meeting
2015 ASCO Annual Meeting
Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.
Authors
Haeseong Park
The University of Texas MD Anderson Cancer Center, Houston, TX
Haeseong Park , Ignacio Garrido-Laguna , Aung Naing , Siqing Fu , Gerald Steven Falchook , Sarina Anne Piha-Paul , Jennifer J. Wheler , David S. Hong , Vivek Subbiah , Apostolia Maria Tsimberidou , Ahmed Omar Kaseb , Yasuhiro Oki , Ralph Zinner , Shreyaskumar Patel , Vivianne Marie Velez Bravo , Michelle A. Fanale , Funda Meric-Bernstam , Razelle Kurzrock , Filip Janku
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT01087554
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2584)
DOI
10.1200/jco.2015.33.15_suppl.2584
Abstract #
2584
Poster Bd #
300
Abstract Disclosures
Similar Posters
Poster
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2022 ASCO Annual Meeting
Phase I study of epacadostat in combination with sirolimus in advanced malignancy.
First Author: Chao Hui Huang